PURE Bioscience (OTCMKTS:PURE) Short Interest Update

PURE Bioscience (OTCMKTS:PURE) was the recipient of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 3,865 shares, a decrease of 65.0% from the June 30th total of 11,031 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 68,596 shares, the short-interest ratio is currently 0.1 days.

PURE Bioscience Price Performance

Shares of PURE stock opened at $0.07 on Wednesday. The firm has a market cap of $9.09 million, a P/E ratio of -2.33 and a beta of 0.22. PURE Bioscience has a 1-year low of $0.04 and a 1-year high of $0.14. The firm has a fifty day moving average of $0.07 and a two-hundred day moving average of $0.07.

PURE Bioscience (OTCMKTS:PURE) last released its earnings results on Monday, June 15th. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.51 million for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.